The success of Sildenafil initially sparked a period of growth for pharma, but recent shifts present a uncertain picture for investors. Off-patent alternatives are eating into revenue, and persistent patent challenges https://keithjsiq741591.sharebyblog.com/41062286/the-blue-pill-and-pharma-a-precarious-play